Accepted answer
Take it from the SURPASS-3 adverse-event table by arm, and check the unit before you use it. An incidence can be the proportion of participants who reported the event at least once, or the count of events divided by exposure time, and the two differ by however many people had it repeatedly. Then subtract the placebo arm, because the untreated rate is not zero. And read the discontinuation column beside it: an event that made people leave the trial is under-counted at every later visit, so a low late-timepoint incidence can mean the event was severe rather than rare.
The honest answer is that this needs an active plan rather than waiting, since it does not usually resolve on its own.
Physical activity has a modest but real effect on transit time and is free, which makes it worth including even though it will not fix this on its own.
Gastrointestinal adverse events, indicative pooled rates
| Event | Active arm | Placebo arm | Timing |
|---|
| Nausea | 40–45 % | 15–20 % | Peaks 1–2 wk after each step |
| Vomiting | 15–25 % | 5–8 % | Follows nausea |
| Diarrhoea | 20–30 % | 10–15 % | Early, variable |
| Constipation | 20–25 % | 8–12 % | Later onset, persistent |
| Discontinuation for GI events | 4–7 % | 1–2 % | Mostly during escalation |
Ranges span agents and doses; read the specific prescribing information for a specific figure.
Aim for 25 to 30 grams of fibre a day, which requires deliberate planning at a reduced total intake because fibre-rich foods are bulky and satiating exactly when appetite is suppressed.
The fibre-and-fluid relationship in functional constipation is established across intervention studies, and fibre without adequate fluid worsens symptoms.
Nothing here is medical advice.
Osmotic first, stimulant reluctantly, and not as a standing arrangement.
3Does the tolerance develop at the same rate for the daily agents? – liam_bracken 8 months ago add a comment